Carl H. June
卡尔·朱恩
MD
Richard W. Vague Professor in Immunotherapy; Director, Center for Cellular Immunotherapies免疫治疗Richard W. Vague讲席教授；细胞免疫治疗中心主任
👥Biography 个人简介
Carl June is the father of modern CAR-T cell therapy. His landmark 2011 trials at Penn demonstrated complete remission in CLL patients using CD19-targeted CAR-T cells, leading directly to FDA approval of tisagenlecleucel—the first gene therapy approved in the United States.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
CAR-T Cell Therapy Pioneer
Developed lentiviral-based CD19 CAR-T constructs with 4-1BB costimulation, achieving complete remissions in CLL and B-ALL and establishing the paradigm for all subsequent CAR-T approvals.
First FDA-Approved CAR-T
Led the clinical program culminating in FDA approval of tisagenlecleucel (Kymriah) in 2017 for pediatric ALL, marking the first approved gene therapy in the US.
Representative Works 代表性著作
Chimeric antigen receptor T cells for sustained remissions in leukemia
New England Journal of Medicine (2014)
Reported durable complete remissions in CLL patients treated with CTL019 (tisagenlecleucel), establishing CAR-T as a transformative cancer therapy.
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
Science Translational Medicine (2011)
Landmark paper reporting the first clinical evidence of CAR-T cell expansion and antitumor efficacy in CLL patients.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 卡尔·朱恩 的研究动态
Follow Carl H. June's research updates
留下邮箱，当我们发布与 Carl H. June（University of Pennsylvania）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment